medroxyprogesterone acetate has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunce, CM; Cronin, LM; Drayson, MT; Hayden, RE; Kussaibati, R; Pratt, G; Roberts, C | 1 |
1 other study(ies) available for medroxyprogesterone acetate and Lymphoma of Mucosa-Associated Lymphoid Tissue
| Article | Year |
|---|---|
Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Bezafibrate; CD40 Ligand; Cell Cycle; Cell Proliferation; Cells, Cultured; Drug Synergism; Female; Flow Cytometry; Humans; L Cells; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Medroxyprogesterone Acetate; Mice; Middle Aged; Mitochondria; Superoxides; Tumor Cells, Cultured | 2015 |